Skip to content

BIOCARTIS

Active
Public limited companyfounded 2010active for 16 yearsGeneraal De Wittelaan 11B, 2800 Mechelen, BelgiumKBO/BCE: BE 0827.475.227
Summary

BIOCARTIS has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €37.2m and a net result of -€22.9m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 52% of 782 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow ReportCompare
BIOCARTISActiveChecked score 92/100
Risk analysis ReportCompare

Overview

Activity
Medical imaging and medical laboratories
NACE 86910Research and development on biotechnology NACE 72101
3rd largest company by equity in Mechelen, Health and social work sector1 site
Size
€48.2mturnover 2025
Staff
205.6 FTE
Equity
€37.2m
Loss
-€22.9m
Financial health
92 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.1%
Structure
Parent
Biocartis Holdings, Inc. · 100%
Holdings
1
Auditor: Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises2025 accounts 53 days early
Why 92raises riskLoss of €22.9m, the second in a row (financial year 2025)lowers riskSector: Human health activities (NACE 86)Size: turnover €48.2m, 205.6 FTE, total assets €61.8mEquity €37.2m (60.2% of total assets)Show the evidence

Checked score

Score 2025
92 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 35% of its sector peers (NACE 86, medium-sized)
Every signal that counts is listed under Signals.
Financial strength · tick = 2024
Average
Solvency 85-13
equity 60.2% of total assets
Liquidity 51-3
short-term debt 27.4% · cash 9.8%
Profitability 0=
return on assets -37.1%
Bankruptcy probability, 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median < 0.1% (84 companies, NACE 86, medium-sized)
Last 24 months 11-2024: 0.3% 12-2024: 0.3%● unchanged vs 11-2024 01-2025: 0.3%● unchanged vs 12-2024 02-2025: 0.3%● unchanged vs 01-2025 03-2025: 0.4%▲ +0.1 percentage points vs 02-2025 04-2025: 0.4%● unchanged vs 03-2025 05-2025: 0.4%● unchanged vs 04-2025highest value 06-2025: 0.1%▼ -0.3 percentage points vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.1%● unchanged vs 07-2025 09-2025: 0.1%● unchanged vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026 07-2026: 0.1%● unchanged vs 06-2026lowest value 08-2026: 0.1%● unchanged vs 07-2026lowest value 09-2026: 0.1%● unchanged vs 08-2026lowest value 10-2026: 0.1%● unchanged vs 09-2026lowest value
Credit of up to €3,400,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.32, compared with 2.61 in 2024, above the usual 1.5; short-term debt: 27.4% and cash: 9.8% of total assets), and 39.8% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, medium-sized): better than 59% on solvency, 48% on liquidity, 3% on profitability and 31% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
raises risk · Loss of €22.9m, the second in a row (financial year 2025)
NBB · annual accounts
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Size: turnover €48.2m, 205.6 FTE, total assets €61.8m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
lowers risk · Equity €37.2m (60.2% of total assets)
NBB · annual accounts
raises risk · Persistent losses
Two consecutive loss-making years (2024 and 2025); equity is also lower. May indicate structural pressure on profitability.
NBB · annual accounts 2025
Net result per financial year
18192122232425
2018 to 2025 · latest year -€22.9m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-06-2026, 53 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
53 days early
2024
77 days early
2023
22 days early
2022
70 days early
2021
75 days early
2020
47 days early
2019
77 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 60 days before the deadline; the sector median (NACE 86) for financial year 2024 is 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 22 May (4 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
31-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Capital & shares · Amendment of…Capital decrease · Shareholding
  2. Reappointment: Deloitte Bedrijfsrevisoren BV / Réviseurs…Power of attorney
  3. Annual accounts filedfinancial year 2025 · full…

Key points

  • Risk: 7 loss-making years in a rowloss financial year 2025 -€22.9m View
  • Caution: Among the weakest 5% on net resultsector median €70,723 · 776 companies -€22.9m View
  • Positive: Filed on time since financial year 2018accounts within the deadline every year 8 years View
  • Flemish supportawarded from 2022 to 2025 €2.1m View
  • Caution: Equity fell in 2025from €51.0m to €37.2m ▼ 27.1% View
  • Known shareholderslargest: Biocartis Holdings, Inc. 100% 100% View

By topic

Financials

Financial year
2025
Turnover
€48.2m
Loss
-€22.9m
Solvency
60.2%
Turnover▲ 4.5%
Net result
20182025
Go to Financials

Board & ownership

Board
1 member
Largest shareholder
Biocartis Holdings, Inc. · 100%
Known shareholders
100%
Auditor
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
  • Randy Brian PolonskyDirector
Go to Board & ownership

Timeline

Events
79
Since
2010
Next accounts
by 31-07-2027
  1. 29-12-2025Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
  2. 04-11-2025Resignation: beNovo BV (permanent representative)
  3. 22-09-2025Capital & shares · Amendment of the…
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Medical imaging and medical laboratoriesNACE 86910
Founded
02-07-2010
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
3
Purpose
“De vennootschap heeft tot voorwerp zowel in België als in het buitenland zowel voor eigen…” (deed in Dutch)
Go to Articles of association

Key facts about BIOCARTIS

What is the company number of BIOCARTIS?
0827.475.227. In Belgium the VAT number is the company number with BE in front: BE 0827.475.227.
Where is BIOCARTIS based?
The registered office is at Generaal De Wittelaan 11B, 2800 Mechelen.Company details
What does BIOCARTIS do?
According to the KBO register, the main activity is medical imaging and medical laboratories (NACE 86910).
What is the legal form of BIOCARTIS?
Public limited company (NV).
When was BIOCARTIS founded?
On 02-07-2010.
Is BIOCARTIS still active?
Yes, BIOCARTIS is an active enterprise in the KBO register.
How many employees does BIOCARTIS have?
On average 205.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of BIOCARTIS?
€48.2m in financial year 2025, according to the filed annual accounts.
Is BIOCARTIS profitable?
In financial year 2025, BIOCARTIS made a loss of €22.9m.
Where can I find the annual accounts of BIOCARTIS?
BIOCARTIS filed 15 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of BIOCARTIS due?
By 31-07-2027, for financial year 2026.Timeline

Companies related to BIOCARTIS

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure